drugset / Trial / NCT05587231

Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK

NCT05587231

Phase 4 Unknown 60 enrolled Navy Medical Center San Diego
RandomizedParallel-groupOpen-labelTreatment

Summary

Naval Refractive Surgery Center proposes a prospective, single-site, randomized, non-FDA regulated clinical trial with bilateral commercial treatment for for PRK. Subjects will be randomized to receive one of two postoperative steroid regimens: Dextenza (a dexamethasone ophthalmic insert) or standard of care topical Fluorometholone. Subjects will be followed for 3 months after surgery. Investigators will use objective and subjective measures to assess potential differences in postoperative healing and pain. This study will not be FDA-regulated. All study surgeries will be standard of care, with the exception of the addition of the Dextenza insert after the PRK procedure among subjects randomized to the Dextenza group.

Timeline

Start
2022-10
Primary completion
2024-10
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other
Comparator Fluorometholone Other / unclassified 0.1 % Topical

Indications

No indication recorded.